Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell roughly 10% on investor worries that the move could blunt its sales momentum.

A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now she fears a deal struck between CVS Health Corp. and Novo Nordisk A/S will undo all that progress.

Eli Lilly & Co has experienced a significant stock price drop of 10.58% over the past week, despite delivering impressive first-quarter results for 2025. The company’s revenue s